All Releases
 |
MiddleBrook Pharmaceuticals Files for Chapter 11 Bankruptcy Protection
Apr 30, 2010
|
13.9 KB |
|
| |
WESTLAKE, Texas, Apr 30, 2010 (BUSINESS WIRE) -- MiddleBrook
Pharmaceuticals, Inc. (NASDAQ: MBRK)
("MiddleBrook" or the "Company") has filed a voluntary petition (the
"Petition") for relief under Chapter 11 of the United States Bankruptcy
Code in the United States Bankruptcy Court for the District of Delaware
...
|
|
MiddleBrook Pharmaceuticals Announces Board of Directors Resignations
Mar 23, 2010
|
9.5 KB |
|
| |
WESTLAKE, Texas, Mar 23, 2010 (BUSINESS WIRE) -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that
James H. Cavanaugh, Ph.D., Martin A. Vogelbaum and Harold R. Werner have
resigned from the Company's Board of Directors effective immediately.
"We thank Jim, Martin and Hal for their contributions to MiddleBrook as...
|
|
MiddleBrook Pharmaceuticals Announces Expanded IncreaseRx(R) Promotion for MOXATAG(R)
Mar 17, 2010
|
14.0 KB |
|
| |
WESTLAKE, Texas, Mar 17, 2010 (BUSINESS WIRE) -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that it
has entered into an agreement with DoctorDirectory.com Inc., the
Company's promotion partner for MOXATAG (amoxicillin extended-release)
Tablets, 775 mg, to expand its previously announced IncreaseRx(R)
...
|
|
MiddleBrook Pharmaceuticals Reports Fourth Quarter 2009 and Full-Year Results; Announces Reduction in Force; Engages Broadpoint Gleacher to Assist in the Evaluation of Strategic Options
Mar 12, 2010
|
36.8 KB |
|
| |
.bwcellpaddingbottom1 {padding-bottom: 2.0px}
.bwcellpaddingbottom3 {padding-bottom: 4.0px}
.bwcellpaddingleft0 {padding-left: 0.0px}
.bwcellpaddingleft1 {padding-left: 5.0px}
.bwcellpaddingleft2 {padding-left: 10.0px}
.bwcellpaddingleft3 {padding-left: 15.0px}
.bwcellpaddingleft5 {padding-left: 25.0px}
.bw...
|
|
MiddleBrook Pharmaceuticals Announces Promotion Partnership with DoctorDirectory.com for MOXATAG® (extended-release amoxicillin) Tablets, 775mg
Feb 3, 2010
|
16.8 KB |
|
| |
.bwtextaligncenter {text-align: center}
.bwunderlinestyle {text-decoration: underline}
WESTLAKE, Texas, Feb 03, 2010 (BUSINESS WIRE) -- ...
|
|
MiddleBrook Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 4350
Jan 5, 2010
|
9.9 KB |
|
| |
WESTLAKE, Texas, Jan 05, 2010 (BUSINESS WIRE) -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) announced today that on
Dec. 31, 2009, it granted options to purchase a total of 5,000 shares of
MiddleBrook's common stock to two (2) new employees as a material
inducement for them to join MiddleBrook. The options were granted...
|
|
MiddleBrook Pharmaceuticals Reduces Field Sales Force and Corporate Staff, Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement
Dec 3, 2009
|
13.2 KB |
|
| |
WESTLAKE, Texas, Dec 03, 2009 (BUSINESS WIRE) -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced a
reduction of its field sales force and corporate staff. Effective
December 4, 2009, MiddleBrook will reduce the number of its sales
managers and field sales representatives by about one-third, to
approx...
|
|
MiddleBrook Pharmaceuticals Reports Third Quarter 2009 Results
Nov 5, 2009
|
29.3 KB |
|
| |
WESTLAKE, Texas, Nov 05, 2009 (BUSINESS WIRE) -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced its
financial and operational results for the quarter ended Sept. 30, 2009.
"MOXATAG tripled its share of the oral-solid penicillin-class antibiotic
market during the 2009 third quarter," said MiddleBrook President and ...
|
|
MiddleBrook Pharmaceuticals Schedules Third Quarter 2009 Results Conference Call and Webcast
Oct 15, 2009
|
11.1 KB |
|
| |
WESTLAKE, Texas--(BUSINESS WIRE)--Oct. 15, 2009--
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is scheduled to
announce its results for the 2009 third quarter on Thursday, Nov. 5,
2009, before...
|
|
MOXATAG® Supports Health Education on FamilyDoctor.org
Oct 12, 2009
|
12.9 KB |
|
| |
WESTLAKE, Texas--(BUSINESS WIRE)--Oct. 12, 2009--
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), the maker of the first
and only FDA-approved once-daily amoxicillin, MOXATAG (extended-release
amoxi...
|
|
MiddleBrook Pharmaceuticals Announces Sales Force Realignment, Cost-Saving Measures
Sep 1, 2009
|
14.4 KB |
|
| |
WESTLAKE, Texas--(BUSINESS WIRE)--Sep. 1, 2009--
MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK) today announced a
strategic realignment of its field sales force to more aggressively
preserve the Company’...
|
|
MiddleBrook Pharmaceuticals Reports Second Quarter 2009 Results
Aug 6, 2009
|
36.8 KB |
|
| |
Highlights:
WESTLAKE, Texas--(BUSINESS WIRE)--Aug. 6, 2009--
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced
financial and operational results for the quarter ended June ...
|
|
MiddleBrook Pharmaceuticals Announces $20 Maximum Copay Program for MOXATAG®
Jul 15, 2009
|
13.6 KB |
|
| |
WESTLAKE, Texas, Jul 15, 2009 (BUSINESS WIRE) -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), announced today that it has implemented a $20 maximum copay program for MOXATAG (amoxicillin extended-release) Tablets, 775 mg. The program is designed to keep a patient's net out-of-pocket copay expense for a MOXATAG prescription at $20 or less. T...
|
|
MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Second Quarter 2009 Financial and Operational Results
Jul 14, 2009
|
10.2 KB |
|
| |
WESTLAKE, Texas--(BUSINESS WIRE)--Jul. 14, 2009-- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is scheduled to announce its financial results for the 2009 second quarter on Thursday, August 6, 2009, before the market opens. At 9:00 a.m. (ET) on that day, MiddleBrook management will conduct a conference call to review results for the 2009 sec...
|
|
MiddleBrook Pharmaceuticals Secures $10 Million Revolving Line of Credit
Jul 1, 2009
|
16.1 KB |
|
| |
WESTLAKE, Texas--(BUSINESS WIRE)--Jul. 1, 2009--
...
|
|
MiddleBrook Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 4350
Jun 3, 2009
|
9.9 KB |
|
| |
WESTLAKE, Texas--(BUSINESS WIRE)--Jun. 3, 2009--
MiddleBrook Pharmaceuticals, Inc. (Nasdaq:MBRK) today announced that on
May 29, 2009, it granted options to purchase a total of 3,600 shares of
Mid...
|
|
MiddleBrook Pharmaceuticals Reports First Quarter 2009 Results
May 7, 2009
|
36.1 KB |
|
| |
...
|
|
MiddleBrook Pharmaceuticals Launches MOXATAG™ Website, Announces Early Prescription Data for MOXATAG
May 1, 2009
|
18.2 KB |
|
| |
WESTLAKE, Texas--(BUSINESS WIRE)--May. 1, 2009--
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) has launched a website
for MOXATAG (extended-release amoxicillin) Tablets, 775 mg. MOXATAG is
the first and only ...
|
|
MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for First Quarter 2009 Financial and Operational Results
Apr 6, 2009
|
10.9 KB |
|
| |
WESTLAKE, Texas, Apr 06, 2009 (BUSINESS WIRE) -- MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK) is scheduled to
announce its financial results for the 2009 first quarter on Thursday,
May 7, 2009, before the market opens. At 9:00 a.m. (ET) on that day,
MiddleBrook management will conduct a conference call to review results ...
|
|
MiddleBrook Pharmaceuticals Launches MOXATAG™, the First and Only FDA-Approved Once-Daily Amoxicillin
Mar 16, 2009
|
13.9 KB |
|
| |
WESTLAKE, Texas--(BUSINESS WIRE)--Mar. 16, 2009--
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today launched MOXATAG
(extended-release amoxicillin) Tablets, 775 mg, the first and only
FDA-approve...
|
|
|
.jpg){kind=small}
.jpg){kind=small}
.jpg){kind=small}
.jpg){kind=small}
.jpg){kind=small}
.jpg){kind=small}
.jpg){kind=small}
.jpg){kind=small}
.jpg){kind=small}